2.4.1.150	diagnostics	GCNT2 is a regulator of epithelial-mesenchymal transition (EMT) and a candidate prognostic indicator of outcome in esophageal squamous cell carcinoma (ESCC) patients	
2.4.1.150	diagnostics	GCNT3 might be an essential glycosylation-related molecule in colorectal cancer and epithelial ovarian cancer progression, with potential interest as a predictive biomarker of response to chemotherapy. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome. Clinical relevance of GCNT3 expression in epithelial ovarian cancer (EOC), role of GCNT3 as a biomarker for cancer patients, overview	
2.4.1.150	medicine	GCNT2 is overexpressed in highly metastatic breast cancer and its expression correlates with adverse pathologic phenotypes. Blocking TGF-beta/GCNT2 signaling is a promising approach for targeting metastatic breast cancer	
2.4.1.150	pharmacology	targeting mucin biosynthesis through GCNT3 may improve drug responsiveness	
2.4.1.150	synthesis	cIGnT6 transfers multiple GlcNAc branches to long linear polylactosamines, a prerequisite for improving enzyme-assisted in vitro synthesis of a type of multivalent sialyl Lewis x glycans that are high affinity inhibitors of lymphocyte L-selectin, enzyme allows general polylactosamine synthesis